Toxicity patterns with immunomodulating antibodies and their combinations

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 423-428

  Haanen, John B A G ^a   Van Thienen, Hans ^a   Blank, Christian U ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; IMMUNOMODULATING AGENT; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADRENAL DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; COLITIS; COUGHING; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DYSPNEA; ENDOPHTHALMITIS; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; HEPATITIS; HUMAN; HYPOPHYSIS DISEASE; HYPOPHYSITIS; HYPOTHALAMUS DISEASE; HYPOTHYROIDISM; IMMUNOLOGICAL TOLERANCE; INFUSION RELATED REACTION; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER INJURY; LIVER TOXICITY; LOSS OF APPETITE; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SARCOIDOSIS; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; THYROID DISEASE; THYROIDITIS; UVEITIS; VITILIGO; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84929156397     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.011     Document Type: Review

References (33)

1. M.E. Keir, Y.E. Latchman, G.J. Freeman, and A.H. Sharpe Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes J Immunol 175 2005 7372 7379
2. X. Chen, D. Fosco, D.E. Kline, L. Meng, S. Nishi, P.A. Savage, and J. Kline PD-1 regulates extrathymic regulatory T-cell differentiation Eur J Immunol 44 9 2014 2603 2616
3. C. Blank, I. Brown, R. Marks, H. Nishimura, T. Honjo, and T.F. Gajewski Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells J Immunol 171 2003 4574 4581
4. B.T. Fife, and J.A. Bluestone Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways Immunol Rev 224 2008 166 182
5. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 1995 541 547
6. H. Nishimura, T. Okazaki, and Y. Tanaka Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 291 2001 319 322
7. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
8. J. Wang, T. Yoshida, F. Nakaki, H. Hiai, T. Okazaki, and T. Honjo Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes Proc Natl Acad Sci U S A 102 2005 11823 11828
9. C.A. Sabatos, S. Chakravarti, and E. Cha Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance Nat Immunol 4 2003 1102 1110
10. A. Sánchez-Fueyo, J. Tian, and D. Picarella Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance Nat Immunol 4 2003 1093 1101
11. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. 1997;94:5744-5749.
12. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. 2011;208:395-407.
13. S.R. Woo, M.E. Turnis, and M.V. Goldberg Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 2012 917 927
14. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. 2010;207:2187-2194.
15. Q. Zhou, M.E. Munger, and R.G. Veenstra Coexpression of Tim-3 and PD-1 identifies a CD8+T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia Blood 117 2011 4501 4510
16. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
17. A. Ribas, R. Kefford, and M.A. Marshall Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 31 2013 616 622
18. F.S. Hodi, S.J. O'Day, and J.A. Sosman Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
19. C. Robert Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
20. J.M. Kirkwood, P. Lorigan, and P. Hersey Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma Clin Cancer Res 16 2010 1042 1048
21. S. O'Day, W. Urba, and J. Powderly Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
22. K.E. Beck, J.A. Blansfield, and K.Q. Tran Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol 24 2006 2283 2289
23. O. Hamid, C. Robert, and F.S. Hodi Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
24. A. Ribas, F.S. Hodi, and R. Kefford Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (mel) J Clin Oncol 32 2014 5s
25. C. Robert, A. Ribas, and J.D. Wolchok Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 2014 1109 1117
26. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
27. S.L. Topalian, D.F. McDermott, and H.M. Kluger Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
28. J.R. Brahmer, S.S. Tykodi, and L.Q.M. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
29. O. Hamid, J. Sosman, and D. Lawrence Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally andvanced or metastatic melanoma (mM) J Clin Oncol 2013 31
30. M.J. Barnes, T. Griseri, A.M.F. Johnson, W. Young, F. Powrie, and A. Izcue CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria Mucosal Immunol 6 2012 324 334
31. T.R. Simpson, F. Li, and W. Montalvo-Ortiz Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J Exp Med 210 2013 1695 1710
32. A. Ferraro, A.M. D'Alise, and T. Raj Interindividual variation in human T regulatory cells Proc Natl Acad Sci U S A 111 2014 E1111 E1120
33. C.J. Voskens, S.M. Goldinger, and C. Loquai The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network PLoS One 8 2013 e53745